FDA panel overwhelmingly votes against experimental ALS treatment pushed by patients
CBSN
Federal health advisers voted overwhelmingly against an experimental treatment for Lou Gehrig's disease at a Wednesday meeting prompted by years of patient efforts seeking access to the unproven therapy.
The panel of Food and Drug Administration experts voted 17-1 that drugmaker Brainstorm's stem cell-based treatment has not been shown effective for patients with the fatal, muscle-wasting disease known as ALS, or amyotrophic lateral sclerosis. One panel member abstained from voting.
While the FDA is not bound by the vote, it largely aligns with the agency's own strikingly negative review released earlier this week, in which staff scientists described Brainstorm's application as "scientifically incomplete" and "grossly deficient."
President Biden on Monday signed into law a defense bill that authorizes significant pay raises for junior enlisted service members, aims to counter China's growing power and boosts overall military spending to $895 billion despite his objections to language stripping coverage of transgender medical treatments for children in military families.
It's Christmas Eve, and Santa Claus is suiting up for his annual voyage from the North Pole to households around the world. In keeping with decades of tradition, the North American Aerospace Command, or NORAD, will once again track Santa's journey to deliver gifts to children before Christmas 2024, using an official map that's updated consistently to show where he is right now.
An anti-money laundering law called the Corporate Transparency Act, or CTA, appears to have been given new life after an appeals court on Monday determined its rules can be enforced as the case proceeds. The law requires small business owners to register with the Financial Crimes Enforcement Network, or FinCEN, by Jan. 1, or potentially pay fines of up to $10,000.